These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 26953344)

  • 1. Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.
    Suryo Rahmanto Y; Jung JG; Wu RC; Kobayashi Y; Heaphy CM; Meeker AK; Wang TL; Shih IeM
    J Biol Chem; 2016 Apr; 291(18):9690-9. PubMed ID: 26953344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
    Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
    J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ARID1A-SIN3A drives retinoic acid-induced neuroblastoma differentiation by transcriptional repression of TERT.
    Bui CB; Le HK; Vu DM; Truong KD; Nguyen NM; Ho MAN; Truong DQ
    Mol Carcinog; 2019 Nov; 58(11):1998-2007. PubMed ID: 31365169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of HDAC-Mediated Repression and Gain of NF-κB Activation Underlie Cytokine Induction in ARID1A- and PIK3CA-Mutation-Driven Ovarian Cancer.
    Kim M; Lu F; Zhang Y
    Cell Rep; 2016 Sep; 17(1):275-288. PubMed ID: 27681437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Allele-Specific Regulation of Telomerase Reverse Transcriptase in Promoter Mutant Thyroid Cancer Cell Lines.
    McKelvey BA; Gilpatrick T; Wang Y; Timp W; Umbricht CB; Zeiger MA
    Thyroid; 2020 Oct; 30(10):1470-1481. PubMed ID: 32228178
    [No Abstract]   [Full Text] [Related]  

  • 6. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation.
    Huang HN; Chiang YC; Cheng WF; Chen CA; Lin MC; Kuo KT
    Mod Pathol; 2015 Feb; 28(2):303-11. PubMed ID: 25081752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers.
    Guan B; Wang TL; Shih IeM
    Cancer Res; 2011 Nov; 71(21):6718-27. PubMed ID: 21900401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tumor suppressor role of chromatin-remodeling factor ARID1A].
    Guo XQ; Zhang QX; Huang WR; Duan XL; Cai ZM
    Yi Chuan; 2013 Mar; 35(3):255-61. PubMed ID: 23575531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARID1A-mutated ovarian cancers depend on HDAC6 activity.
    Bitler BG; Wu S; Park PH; Hai Y; Aird KM; Wang Y; Zhai Y; Kossenkov AV; Vara-Ailor A; Rauscher FJ; Zou W; Speicher DW; Huntsman DG; Conejo-Garcia JR; Cho KR; Christianson DW; Zhang R
    Nat Cell Biol; 2017 Aug; 19(8):962-973. PubMed ID: 28737768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response.
    Mandal J; Mandal P; Wang TL; Shih IM
    J Biomed Sci; 2022 Sep; 29(1):71. PubMed ID: 36123603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
    Yuan X; Larsson C; Xu D
    Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations and telomeres during tumorigenesis.
    Lorbeer FK; Hockemeyer D
    Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential therapeutic targets in ARID1A-mutated cancers.
    Bitler BG; Fatkhutdinov N; Zhang R
    Expert Opin Ther Targets; 2015; 19(11):1419-22. PubMed ID: 26125128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTCF mediates the TERT enhancer-promoter interactions in lung cancer cells: identification of a novel enhancer region involved in the regulation of TERT gene.
    Eldholm V; Haugen A; Zienolddiny S
    Int J Cancer; 2014 May; 134(10):2305-13. PubMed ID: 24174344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer.
    Fukumoto T; Park PH; Wu S; Fatkhutdinov N; Karakashev S; Nacarelli T; Kossenkov AV; Speicher DW; Jean S; Zhang L; Wang TL; Shih IM; Conejo-Garcia JR; Bitler BG; Zhang R
    Cell Rep; 2018 Mar; 22(13):3393-3400. PubMed ID: 29590609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E2F-1 represses transcription of the human telomerase reverse transcriptase gene.
    Crowe DL; Nguyen DC; Tsang KJ; Kyo S
    Nucleic Acids Res; 2001 Jul; 29(13):2789-94. PubMed ID: 11433024
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromatin accessibility underlies synthetic lethality of SWI/SNF subunits in ARID1A-mutant cancers.
    Kelso TWR; Porter DK; Amaral ML; Shokhirev MN; Benner C; Hargreaves DC
    Elife; 2017 Oct; 6():. PubMed ID: 28967863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional analysis of in-frame indel ARID1A mutations reveals new regulatory mechanisms of its tumor suppressor functions.
    Guan B; Gao M; Wu CH; Wang TL; Shih IeM
    Neoplasia; 2012 Oct; 14(10):986-93. PubMed ID: 23097632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase variant A279T induces telomere dysfunction and inhibits non-canonical telomerase activity in esophageal carcinomas.
    Zhang Y; Calado R; Rao M; Hong JA; Meeker AK; Dumitriu B; Atay S; McCormick PJ; Garfield SH; Wangsa D; Padilla-Nash HM; Burkett S; Zhang M; Kunst TF; Peterson NR; Xi S; Inchauste S; Altorki NK; Casson AG; Beer DG; Harris CC; Ried T; Young NS; Schrump DS
    PLoS One; 2014; 9(7):e101010. PubMed ID: 24983628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.